/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Immunovant, Inc. ( Immunovant, we or the Company ) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor ( FcRn ), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (…
$36.95
$0.70 (-1.86%)
EOD Sep 18, 2026
Negative free cash flow of -$407M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$538M
▼ -22.2% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$414M
▼ -8.1% YoY
Op. Cash Flow (TTM)
-$414M
▼ -8.4% YoY
Net Debt
-$798M
Net Cash Position
Cash & Equiv.
$798M
Continue Research
SourceComputed from the 10-Q filed 6 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Mar. Sector medians are approximate S&P 500 benchmarks and update periodically.